Advertisement
Canada markets open in 43 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7295
    -0.0003 (-0.04%)
     

  • CRUDE OIL

    83.10
    +0.29 (+0.35%)
     

  • Bitcoin CAD

    87,366.30
    -3,623.90 (-3.98%)
     

  • CMC Crypto 200

    1,364.45
    -18.12 (-1.31%)
     

  • GOLD FUTURES

    2,337.80
    -0.60 (-0.03%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6920
    +0.0400 (+0.86%)
     

  • NASDAQ futures

    17,414.50
    -250.00 (-1.42%)
     

  • VOLATILITY

    16.62
    +0.65 (+4.07%)
     

  • FTSE

    8,088.46
    +48.08 (+0.60%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6822
    +0.0003 (+0.04%)
     
MARKETS LIVE BLOG:

STOCK FUTURES SLIDE AFTER META'S REALITY CHECK, WITH GDP ON DECK

Owner of Facebook and Instagram plans to spend up to US$10B on AI infrastructure investments

Today’s Research Reports on Annidis, Antibe Therapeutics, BLVD Centers and Cotinga Pharmaceuticals

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / March 26, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Annidis Corporation
https://rdinvesting.com/news/?ticker=RHA.V

Antibe Therapeutics Inc.
https://rdinvesting.com/news/?ticker=ATE.V

BLVD Centers Corporation
https://rdinvesting.com/news/?ticker=CXV.V

Cotinga Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=COT.V

ADVERTISEMENT

Annidis' stock had no change Friday, to close the day at $0.01. The stock recorded a trading volume of 34,200 shares, which was below its three months average volume of 200,160 shares. In the last year, Annidis' shares have traded in a range of 0.00 - 0.04. The stock is currently trading 75.00% below its 52 week high. The company's shares are currently trading at their 200-day moving average. The stock's 50-day moving average of $0.01 is at its 200-day moving average of $0.01.

Access RDI's The Annidis Corporation Research Report at:
https://rdinvesting.com/news/?ticker=RHA.V

On Friday, shares of Antibe Therapeutics recorded a trading volume of 2,569,428 shares, which was above the three months average volume of 2,078,783 shares. The stock ended the day 5.77% lower at 0.49. The share price has gained 512.50% from its 52-week low with a 52-week trading range of 0.08 - 0.79. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.30 is greater than its 200-day moving average of $0.17. Shares of Antibe Therapeutics have gained approximately 237.93 percent year-to-date.

Access RDI's Antibe Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ATE.V

BLVD Centers' stock fell 11.11% Friday, to close the day at $0.08. The stock recorded a trading volume of 137,108 shares, which was below its three months average volume of 1,619,300 shares. In the last year, BLVD Centers' shares have traded in a range of 0.08 - 0.19. The stock is currently trading 57.89% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.09 is below its 200-day moving average of $0.10. Shares of BLVD Centers have fallen approximately 5.88 percent year-to-date.

Access RDI's BLVD Centers Corporation Research Report at:
https://rdinvesting.com/news/?ticker=CXV.V

On Friday, shares of Cotinga Pharmaceuticals recorded a trading volume of 71,700 shares, which was above the three months average volume of 19,014 shares. The stock ended the day flat at 0.47. The share price has gained 34.29% from its 52-week low with a 52-week trading range of 0.35 - 4.90. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.66 is below its 200-day moving average of $0.98. Shares of Cotinga Pharmaceuticals have fallen approximately 57.27 percent year-to-date.

Access RDI's Cotinga Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=COT.V

Our Actionable Research on Annidis Corporation (TSXV:RHA.V), Antibe Therapeutics Inc. (TSXV:ATE.V), BLVD Centers Corporation (TSXV:CXV.V) and Cotinga Pharmaceuticals Inc. (TSXV:COT.V) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com